TCGA-FD-A3SP-01A-31R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 25.72273325
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.640
- HEDGEHOG_SIGNALING+0.550
- IL6_JAK_STAT3_SIGNALING+0.500
- ANGIOGENESIS+0.460
- INFLAMMATORY_RESPONSE+0.460
- UV_RESPONSE_DN+0.460
- ALLOGRAFT_REJECTION+0.440
- TGF_BETA_SIGNALING+0.420
- INTERFERON_GAMMA_RESPONSE+0.410
- WNT_BETA_CATENIN_SIGNALING+0.400
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.410
- MYC_TARGETS_V2-0.350
- MYC_TARGETS_V1-0.320
- PEROXISOME-0.310
- KRAS_SIGNALING_DN-0.250
- ESTROGEN_RESPONSE_LATE-0.240
- PANCREAS_BETA_CELLS-0.240
- CHOLESTEROL_HOMEOSTASIS-0.210
- FATTY_ACID_METABOLISM-0.200
- ADIPOGENESIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.916 |
| 2 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.904 |
| 3 | TCGA-63-A5MN-01A-22R-A27Q-07 | — | cohortA1 | 0.896 |
| 4 | MDT-AP-0390 | Med | Medulloblastoma | 0.895 |
| 5 | SAMN03290911 | — | — | 0.890 |
| 6 | SRR23303739 | — | — | 0.882 |
| 7 | TCGA-43-6647-01A-11R-1820-07 | — | cohortSQ1 | 0.877 |
| 8 | TCGA-56-6545-01A-11R-1820-07 | — | cohortSQ1 | 0.873 |
| 9 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.872 |
| 10 | TCGA-XF-AAMT-01A-11R-A42T-07 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.640 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.550 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |